ACTEMRA SC injections using the prefilled syringe and the ACTEMRA ACTPen® autoinjector have been studied in 4 clinical trials including almost 1,800 people living with moderate to severe rheumatoid arthritis (RA). The studies tested how well ACTEMRA SC injections worked for RA patients, and the side effects associated with ACTEMRA.
Two key clinical trials, called BREVACTA and SUMMACTA, showed that ACTEMRA SC injections taken with DMARDs:
Reduced the signs and symptoms of RA
Decreased the progression of joint damage when taken with DMARDs
Helped reduce swollen and tender joints
Eased some daily living activities for some RA patients
Your healthcare provider should do blood tests before you start receiving ACTEMRA. If you have rheumatoid arthritis (RA) your healthcare provider should do blood tests 4 to 8 weeks after you start receiving ACTEMRA for the first 6 months and then every 3 months after that. These blood tests are to check for the following side effects of ACTEMRA:
Your healthcare provider will determine how often you will have follow-up blood tests. Make sure you get all your follow-up blood tests done as ordered by your healthcare provider.
You should not receive ACTEMRA if your neutrophil and platelet counts are too low or your liver function test levels are too high. Changes in blood test results may cause your healthcare provider to stop your ACTEMRA treatment for a time or change your dose.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.